Company & Sponsor Intelligence
University of Massachusetts, Worcester
Evidence-linked intelligence derived from the current NeuroRisk clinical research corpus. Coverage reflects indexed source data and is not a claim of complete company activity.
Request enterprise analysis →Indexed trials6
Recruiting2
Completed4
Countries1
Therapeutic footprint
alzheimersautismdepressionother_psychiatrysubstance_use
Indexed studies
NCT03589898Study of Neuroimaging Biomarkers of Social Cognition Deficits in Adolescents (Age 13-17) With Autism Spectrum Disorder and Effects of Gabapentin
autism · United StatesEARLY_PHASE1
autism · United StatesEARLY_PHASE1
NCT05138614Supporting Treatment Access and Recovery in COD
substance_use · United StatesNA
substance_use · United StatesNA
NCT01320527A Clinical Trial of a Vitamin/Nutriceutical Formulation for Alzheimer's Disease
alzheimers · United StatesPHASE2
alzheimers · United StatesPHASE2
NCT07418047Preliminary Trial of an Avatar Guided Digital Intervention for Emerging Adults
other_psychiatry · United StatesNA
other_psychiatry · United StatesNA
NCT04919967Online Training for Addressing Perinatal Depression
depression · United StatesNA
depression · United StatesNA
NCT02760004PRogram In Support of Moms: An Innovative Stepped-Care Approach for Obstetrics and Gynecology Clinics
depression · United StatesNA
depression · United StatesNA
Intelligence layer updated: 2026-10-11 23:31:09.606883+00:00
Enterprise intelligence
Compare sponsor activity, recruiting momentum, therapeutic exposure, geography and connected research signals across the neuroscience ecosystem.
Request comparative intelligence →